ValuEngine downgraded shares of Galectin Therapeutics Inc. (NASDAQ:GALT) from a sell rating to a strong sell rating in a research report sent to investors on Thursday.

Separately, Zacks Investment Research downgraded shares of Galectin Therapeutics from a buy rating to a hold rating in a research report on Tuesday, July 18th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $2.25.

Shares of Galectin Therapeutics (NASDAQ GALT) traded up 2.0214% during midday trading on Thursday, reaching $1.9179. 63,076 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $1.79 and its 200 day moving average price is $2.29. Galectin Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.68. The stock’s market capitalization is $67.22 million.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the company earned ($0.20) earnings per share. On average, equities analysts predict that Galectin Therapeutics will post ($0.56) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Galectin Therapeutics Inc. (GALT) Downgraded to Strong Sell at ValuEngine” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/22/galectin-therapeutics-inc-galt-downgraded-to-strong-sell-at-valuengine.html.

Several institutional investors have recently modified their holdings of the company. KCG Holdings Inc. boosted its holdings in shares of Galectin Therapeutics by 1.9% in the 1st quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock valued at $198,000 after buying an additional 1,592 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Galectin Therapeutics by 4.4% in the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after buying an additional 3,176 shares in the last quarter. Virtu KCG Holdings LLC boosted its holdings in shares of Galectin Therapeutics by 24.4% in the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after buying an additional 21,008 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Galectin Therapeutics by 30.9% in the 1st quarter. US Bancorp DE now owns 118,921 shares of the company’s stock valued at $274,000 after buying an additional 28,087 shares in the last quarter. Finally, Advisor Group Inc. boosted its holdings in shares of Galectin Therapeutics by 10.4% in the 2nd quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock valued at $1,191,000 after buying an additional 45,700 shares in the last quarter. Institutional investors and hedge funds own 11.18% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.